PAREXEL International Appoints Simon Harford as Senior Vice President and Chief Financial Officer
February 28 2017 - 7:00AM
Business Wire
Appointment Effective June 1, 2017
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced the
appointment of Simon Harford as Senior Vice President and Chief
Financial Officer effective June 1, 2017. He will serve on
PAREXEL's Business Review Committee, the Company's senior-most
leadership team, and assist in developing and implementing
PAREXEL's strategic objectives. Mr. Harford will be based at the
Company’s corporate headquarters in Waltham, Massachusetts.
“Simon brings to PAREXEL more than three decades of global
financial management and investor relations experience in the
pharmaceutical industry. During his career, he has successfully
managed large global finance functions, implemented
transformational projects, and improved operational effectiveness,”
said Josef von Rickenbach, Chairman and Chief Executive
Officer, PAREXEL. “Simon’s leadership will strengthen our ability
to accelerate growth and improve profitability as we implement our
corporate strategy.”
Mr. Harford joins PAREXEL from GlaxoSmithKline plc (GSK), where
he most recently served as Senior Vice President, Finance, for the
company’s Global Pharmaceuticals business based at GSK’s global
headquarters in Brentford, England. Prior to joining GSK, Mr.
Harford served as Group Vice President and Controller for Avon
Products, Inc., in New York. Additionally, he spent two decades
with Eli Lilly and Company in various finance leadership roles
across Europe and in Indianapolis, most notably as Head of Investor
Relations and as Vice President and Controller.
“PAREXEL has a long and distinguished history of providing
innovative services to the biopharmaceutical industry, a record
that has positioned the Company for long-term growth,” said Mr.
Harford. “I look forward to working with PAREXEL’s management team
as we leverage growth opportunities and deliver value to our
shareholders.”
Mr. Harford, a native of the United Kingdom, holds an MBA from
the University of Virginia’s Darden Graduate School of
Business.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 85 locations in 51 countries around the
world, and had approximately 19,625 employees in the second
quarter. For more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170228005476/en/
Media:Erik KoppTel.: +1 781-434-5304Email:
erik.kopp@PAREXEL.comorJenny Radloff, PAN CommunicationsTel: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1-781-434-4753Email: ron.aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024